Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
An Open Label, Multi-Center, Phase II Study to Investigate the Safety and Efficacy of SDX-101
(R-Etodolac) in Patients with Relapsed or Refractory Multiple Myeloma (MM)